Definitive concurrent chemoradiotherapy outcomes in Stage IIIB nonsmall cell lung cancer patients younger than 45 years: A retrospective analysis of 145 patients

dc.contributor.authorTopkan, Erkan
dc.contributor.authorGuler, Ozan Cem
dc.contributor.authorOzdemir, Yurday
dc.contributor.orcID0000-0001-6908-3412en_US
dc.contributor.orcID0000-0002-2218-2074en_US
dc.contributor.orcID0000-0001-8120-7123en_US
dc.contributor.pubmedID32930115en_US
dc.contributor.researcherIDAAC-5654-2020en_US
dc.contributor.researcherIDAAG-5629-2021en_US
dc.contributor.researcherIDAAG-2213-2021en_US
dc.date.accessioned2021-04-16T06:42:01Z
dc.date.available2021-04-16T06:42:01Z
dc.date.issued2020
dc.description.abstractPurpose: To assess the survival outcomes and prognostic factors of young (<= 45 years) Stage IIIB nonsmall cell lung cancer (NSCLC) patients treated with definitive concurrent chemoradiotherapy (C-CRT). Materials and Methods: Medical records of 145 Stage IIIB NSCLC patients (<= 45 years) who received 60-66 Gy thoracic radiotherapy and concurrent 1-3 cycles of cisplatin-based doublet chemotherapy were retrospectively evaluated. The primary endpoint was overall survival (OS), while locoregional progression-free survival (LRPFS), progression-free survival (PFS), and evaluation of potential prognostic factors constituted the secondary endpoints. Results: At median 21.6 months (range: 7.3-62.5) of follow-up, the median and 4-year survival estimates were 24.8 months and 24.2% for OS, 15.7 months and 18.9%, for LRPFS and 12.0 months and 11.2% for PFS, respectively. On univariate analyses, among all factors, the smaller tumor size (<= 7.0 cm; P = 0.03), lower T-stage (T1-T2; P = 0.02), lower N-stage (N2; P = 0.01), absence of anemia before C-CRT (hemoglobin [Hb] >= 12 g/dL; P < 0.001), and lower/no pretreatment weight loss (WL <less than or equal to>5%; P < 0.001) were found to be associated significantly with longer median OS durations, which also retained their independent significance on multivariate analyses, except for tumor size category. Conclusions: The encouraging median 24.8 months OS duration observed here in young NSCLC patients accords well with the results of recent landmark locally advanced NSCLC series without age stratification. Other than the well-established T and N stages, extra exhibit of superior OS in patients with initial Hb <greater than or equal to>12 g/dL and <= 5% WL levels suggests a noteworthy prognostic role for these two latter variables in the stratification of such patients.en_US
dc.identifier.endpage763en_US
dc.identifier.issn0973-1482en_US
dc.identifier.issue4en_US
dc.identifier.scopus2-s2.0-85091051379en_US
dc.identifier.startpage757en_US
dc.identifier.urihttps://www.cancerjournal.net/temp/JCanResTher164757-4722789_130707.pdf
dc.identifier.urihttp://hdl.handle.net/11727/5686
dc.identifier.volume16en_US
dc.identifier.wos000585412200010en_US
dc.language.isoengen_US
dc.relation.isversionof10.4103/jcrt.JCRT_1063_16en_US
dc.relation.journalJOURNAL OF CANCER RESEARCH AND THERAPEUTICSen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergien_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectConcurrent chemoradiotherapyen_US
dc.subjectnonsmall cell lung canceren_US
dc.subjectyoung patientsen_US
dc.titleDefinitive concurrent chemoradiotherapy outcomes in Stage IIIB nonsmall cell lung cancer patients younger than 45 years: A retrospective analysis of 145 patientsen_US
dc.typearticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
JCanResTher164757-4722789_130707.pdf
Size:
768.15 KB
Format:
Adobe Portable Document Format
Description:

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: